Copies of letters sent to healthcare professionals in February 2013, to inform of new safety information and advice:
| Date sent | Medicine | Safety information |
|---|---|---|
| 20 February 2013 | Denosumab 60mg (Prolia▼) (108Kb) |
Rare risk of atypical femoral fracture noted with Prolia use in a clinical trial. |
| 25 February 2013 | Botulinium Toxin Type B (Neurobloc) (136Kb) |
Rare cases of distant toxin spread have been reported with Neurobloc; most of these cases occurred with off-label use. |
| 28 February 2013 | Synarel nasal spray (131Kb) |
Restricted supply of Synarel 2 mg/mL (8 mL bottles) – product allocation is restricted to mid-cycle patients only. |
| 28 February 2013 | Gadoversetamide injection (Optimark) (208Kb) |
Peel-off tracking labels have been introduced for all gadolinium-containing contrast agents, in order to trace their use. |